Swedish biotechnology company Cantargia AB (STO:CANTA) on Monday reported positive results from two clinical trials evaluating nadunolimab in combination therapy for cancer patients.

The data suggest that nadunolimab may be effective in patients who have progressed on pembrolizumab treatment, particularly those with a specific profile of immune and immunosuppressive cells in the tumour microenvironment. The clinical trials demonstrated encouraging median survival times and disease control rates in these patients.

Cantargia said that the findings highlight the potential of nadunolimab for patients with limited treatment options after progressing on immunotherapy.